Palbace Drug Description

Drug Class and Categories: Palbace is classified as a CDK4/6 inhibitor and falls under the oncology and antineoplastic agent categories. It is primarily used in the treatment of hormone receptor-positive breast cancer.

Active Ingredient and Other Names:

• Active Ingredient: Palbociclib

• Popular and Other Names:

  • Brand Name: Palbace

  • Chemical Name: Palbociclib

  • Alternate Names: PD 0332991, Ibrance (brand name for Palbociclib)

Mode of Action: Palbace (Palbociclib) functions by inhibiting cyclin-dependent kinase 4 (CDK4) and cyclin-dependent kinase 6 (CDK6), which are essential for cell cycle progression. By blocking these enzymes, Palbace disrupts the proliferation of cancer cells, particularly those in hormone receptor-positive breast cancer. This mechanism helps to slow down or halt tumor growth and prevent cancer from spreading.

How to Use It:

• Administration: Palbace is administered orally in tablet form.

• Usage: Take the tablets by mouth with or without food, according to the dosage prescribed by your healthcare provider.

Recommended Dosage:

• Standard Dosage: Typically, the dosage is 125 mg taken once daily for 21 days, followed by a 7-day break to complete a 28-day treatment cycle.

• Dosage Adjustments: Dosage may be adjusted based on individual tolerance, side effects, and blood test results. Always follow the healthcare provider's instructions for any dosage changes.

Directions:

• Administration: Swallow the tablets whole with a glass of water. Do not crush, chew, or split the tablets.

• Missed Dose: If you miss a dose, take it as soon as you remember, unless it is almost time for your next dose. Do not double the dose to make up for a missed one.

Cautions:

• Pregnancy and Breastfeeding: Avoid using Palbace during pregnancy and breastfeeding. Consult with your healthcare provider about potential risks and alternative treatments.

• Pre-existing Conditions: Inform your healthcare provider of any liver disorders, infections, or blood disorders before starting Palbace.

• Drug Interactions: Be aware of potential interactions with other medications. Provide a complete list of all drugs, vitamins, and supplements you are taking to your healthcare provider.

Manage Side Effects:

• Common Side Effects: Nausea, fatigue, loss of appetite, diarrhea, and mouth sores are commonly reported.

• Severe Side Effects: Monitor for severe infections, low blood cell counts, or liver problems. Contact your healthcare provider if you experience symptoms such as fever, unusual bleeding, or jaundice.

Guidelines:

• Storage: Store Palbace at room temperature, away from moisture and heat. Keep it in its original container and out of reach of children.

• Monitoring: Regular blood tests may be required to monitor blood cell counts and liver function throughout the treatment period.

• Overdose: In case of an overdose, seek immediate medical help. Symptoms may include severe nausea, vomiting, or unusual bleeding.

Frequently Asked Questions (FAQs):

1. What is Palbace used for?
   Palbace (Palbociclib) is used to treat hormone receptor-positive breast cancer, often in combination with other hormonal therapies.

2. How should Palbace be taken?
   Palbace is taken orally in tablet form, usually once daily for 21 days, followed by a 7-day break in a 28-day cycle. Follow your healthcare provider’s instructions for usage.

3. What are the common side effects of Palbace?
   Common side effects include nausea, fatigue, decreased appetite, diarrhea, and mouth sores.

4. What should I do if I miss a dose of Palbace?
   If you miss a dose, take it as soon as you remember unless it is almost time for your next dose. Avoid taking two doses at once.

5. Are there any precautions I should take while using Palbace?
   Yes, avoid Palbace during pregnancy and breastfeeding, and inform your healthcare provider of any liver conditions or drug interactions.

6. Can Palbace be used with other treatments?
   Palbace is often used in combination with other hormonal therapies for enhanced effectiveness in treating hormone receptor-positive breast cancer.